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Clinical testing of the nutraceuticals glucosamine (glcN) and chondroitin sulfate (CS) has shown
efficacy in providing relief from symptoms in osteoarthritic patients. In vitro and in vivo studies support
existence of a synergistic relationship upregulating synthetic activity in chondrocytes. A combination
of glcN and CS may also be useful as adjunct therapy in sports-related injuries if similar upregulation
of collagen synthesis is elicited in accessory ligament and tendon joint tissue. Collagen and non-
collagenous protein (NCP) synthesis in cultures of bovine tenocytes, ligament cells and chondrocytes
exposed to glcN þ CS were assayed by uptake of radiolabeled proline into collagenase-sensitive
material. Assay of radiolabel in hydroxyproline (a specific marker for collagen synthesis) following
HPLC isolation confirmed the specificity of the metabolic effect. Synthesis of total collagenase-
sensitive material was maximally upregulated at physiologically obtainable doses of glcN þ CS. Tissue
response followed the sequence ligament cells (þ69%) > chondrocytes (þ56%) > tenocytes (þ22%).
Labeled hydroxyproline increased by 132% in ligament cells, 27% in tenocytes and 49% in epitendon
cells after a 48 h exposure to 5 mgm l
 1 glcN þ 4 mgm l
 1 CS. Low dose combinations of glcN and CS
effectively stimulate in vitro collagen and NCP synthesis by ligament cells, tenocytes and chondrocytes.
Hence, therapeutic use following accessory joint tissue trauma may help augment repair processes.
Keywords: arthritis – metabolism alternative therapy
Introduction
The combination of glucosamine (glcN) and chondroitin
sulfate (CS) has been extensively tested for clinical efficacy
of symptomatic relief in patients with osteoarthritic (OA)
joints (1–4). Assessment of joint cartilage degeneration and
anti-inflammatory effects has also been examined in diverse
animal models of arthritis (5–8). In addition, in vitro and in
vivo studies support existence of a synergistic relationship of
these two agents associated with upregulation of matrix
proteoglycan synthesis and downregulation of metalloprotease
activity (1,9–11) suggesting a ‘chondroprotective’ effect. For
the most part, these studies have only examined responses of
articular chondrocytes but conceptually OA is considered a
disorder of the entire articulating joint including the ligament
and tendon accessory joint structures (12).
Ligaments and tendons are dense fibrous connective tissues
providing mechanical stability to joints during movement. The
cellular fibroblastic-like cells are surrounded by an organized
fibrous extracellular matrix composed primarily of type
I collagen, elastin, non-collagenous proteins (NCP), and
small amounts of keratan and CS. Aging-related alterations
or trauma to tendons and ligaments play a role in altering joint
dynamics and predispose the joint to early onset of osteoar-
thritis (13,14). Tendon/ligament failure by traumatic rupture,
overuse and/or inflammatory processes is ranked as the 15th
most common musculoskeletal condition and 30–50% of all
sports injuries (15). Moreover, the annual incidence of acute
rupture of the anterior cruciate ligament has been estimated to
be one in 3000 in the American population, with  95000 new
cases per year (16).
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emphasize non-steroidal anti-inflammatory agents (NSAIDs)
to minimize inflammation and subsequent damage to tissue
integrity. However, caution has been recommended against
excessive use of some NSAIDs since these agents have an
inhibitoryeffectonproteoglycansynthesis and cellproliferation
(17) and in animal models do not provide any biochemical
benefit (18). A number of growth promoting factors including
platelet-derived growth factor, transforming growth factor beta
and basic fibroblastgrowthfactorhavedemonstratedsignificant
stimulation of matrix synthesis in vitro but have not proved
successful in vivo (19). There is currently no efficacious therapy
for enhancing the rate and/or ability of these tissues to heal (17).
Nutraceutical supplements including creatine, ephedra, etc.,
have been associated with side effects and lack rigorous quality
assurance to warrant their use (20).
Clinical trials using nutraceutical preparations for healing
and minimizing inflammatory processes in dense connective
tissues have not been performed. The significant advantage
of such therapy for sports-related injuries is the possibility
of enhancing natural repair processes and/or minimizing
NSAIDs use.
The rationale for exploring whether the combination of
glcN þ CS has a beneficial effect on collagen synthesis in
ligaments and tendons is based on previous studies suggesting
that they act as biological response modifiers upregulating
metabolic activity of chondrocytes (10). Since the cells
of ligament/tendon tissue have a similar origin as articular
chondrocytes, exhibit similar aging-related changes in meta-
bolism and mechanical properties (21), are less responsive to
repair stimuli (22) and are capable of maintaining normal
remodeling processes (23), it was of interest to examine
whether they respond in similar fashion as articular chondro-
cytes. Moreover, the majority of published studies with these
agents have been on articular cartilage examining proteogly-
can synthesis and degradation and anti-inflammatory activity.
Little is known of their effect on collagen synthesis, a major
component of cartilage as well as dense connective tissue. To
this end, we took advantage of the availability of a commercial
preparation, Cosamin DS (CDS; Nutramax Laboratories Inc.,
Edgewood, MD), a mixture of glucosamine HCl (FCHG49 ,
99% purity), CS (TRH122 , 98% purity) and manganese
ascorbate in the ratio 5:4:1 for which numerous clinical
and in vitro data are available. The material was used as a
combination rather than testing of individual components
since previous data indicates that both agents exert an
upregulation of synthetic activity of chondrocytes, but the
combination of agents has greater efficacy clinically (1) as
well as acting synergistically on articular cartilage in vitro (8).
Materials and Methods
Articular cartilage was obtained from the articulating surfaces
of metacarpal joints of 3- to 5-year-old Holstein cows.
Ligament tissue was resected from between the 3rd and 4th
metacarpal bones and a large segment of the extensor tendon
was excised from an area adjacent to the metacarpal joint.
All three minced tissues were digested with Type I (tendon
and ligament) or Type II (cartilage) bacterial collagenase
(Sigma/Aldrich Chemical Co., St Louis, MO) at 220 units
ml
 1.The cell population was expanded by culturing in 75 cm
2
flasks containing DMEM/F-12 þ 10% fetal calf serum,
50 mgm l
 1 ascorbic acid 2-sulfate and antibiotics. In some
studies, the epitenon was dissected from the tendon and
cultured separately. After a single passage, sufficient cells
were obtained for seeding into multiplate wells. All cultures
were brought to a metabolic steady-state by culturing for an
additional 5 days in DMEM/F-12 þ 10% FCS. Twenty-four
hours prior to testing, cell cultures were acclimated to DMEM/
F-12 with 1% fetal calf serum, 50 mgm l
 1 ascorbic acid and
5 mM glucose. All subsequent studies were done with media
containing physiological levels of glucose (5 mM) and varying
doses of CDS. Two methods were utilized to monitor
neosynthesis of collagen and NCP.
Method 1: Incorporation of Tritiated Proline (pro)
into Collagenase-Sensitive Material
Cells cultured in 24-well plates at a high density of 200000
cells per well were exposed at 37 C for 24 h to CDS at doses of
1, 10, 50 and 100 mgm l
 1 and 5 mCi ml
 13 H-proline (specific
activity 97 Ci mM
 1). There were eight replicates/treatments
in a total media volume of 0.5 ml. IGF-1 at 50 ng ml
 1 was
used as a positive control. Cultures were terminated by freeze-
thawing and sonication to rupture cells. Soluble collagen and
NCP synthesis were assayed following the addition of 50%
trichloroacetic acid (TCA) to precipitate all proteins contained
in the combined cell layer and media (final TCA concentration
5%). The plates were centrifuged at 3000 r.p.m. in microplate
carriers for 15 min and the supernatant removed. TCA (5%
containing 1 mM proline) precipitation was repeated until the
supernate was free of unincorporated radiolabel. Residual
TCA was removed by a final rinse of ethanol:ethyl ether (1:1)
and the culture plates air dried.
Assay of collagenase-sensitive material was done according
to the method of Diegelmann et al. (24) Briefly, collagen in the
TCA precipitated air-dried plates was digested by adding an
incubation cocktail containing 25 mg purified collagenase
(Worthington Biochemical Corp., Lakewood, NJ) in 200 mlo f
0.05 M Tris (pH 7.6) containing 0.005 M CaCl2. The plates
were incubated for 3 h at 37 C. The supernatant was removed
after centrifugation and the collagenase digestion repeated a
second time. Radioactivity in the pooled supernates (total
collagen fraction) was counted in multiplate wells after
addition of 300 ml of scintillant (Hewlett Packard) to 100 ml
of sample. The residue (NCP) was dissolved by heating at
50 C in 1 N NaOH for 15 min and similar aliquots were
counted as described above. The data are expressed as CPM ±
SEM associated with collagenase-sensitive material and NCP.
Unless otherwise stated, all tendon cultures consisted of a
mixture of three cell types: sheath fibroblasts, epitenon and
endotendon tenocytes.
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In repeat experiments, cells seeded at a density of 500000
per well in 12-well multiplates were treated for 48 h with
10 mgm l
 1 CDS. The supernate from the collagenase
digestion (total collagen fraction) was made up to 6 N HCl
with concentrated acid and hydrolyzed at 120 C under vacuum
for 24 h. After evaporation of the HCl, the amino acid residue
was dansylated by adding 100 ml of 500 mM NaHCO3 and
100 ml of 20 mM Dns-Cl in acetone to 100 ml of hydrolyzed
sample. Samples were reacted in the dark for 40 min at 65 C.
High-pressure liquid chromatography (HPLC) separation of
the dansylated imino acids was accomplished on a Ultrasphere
ODS C-18 (250 mm · 4.6 mm) column using a stepwise
gradient of 25 mM NaH2PO2 þ 25 mM acetic acid/acetonitrile
(86:14) (Solvent A) and 100% acetonitrile (Solvent B) (25).
Peaks corresponding to authentic hyp and pro were collected
and assayed for incorporated radioactivity and quantitated by
comparison with known standards. The data were expressed as
specific activity (cpm hyp or pro mg
 1 hyp or pro).
Statistical Analysis
The cell culture data were expressed as the mean CPM ± SEM.
Experiments were done with cells from different animals to
insure the validity of the results. The percent change from
control cultures was also calculated and the means compared
using ANOVA and Student’s t-test for multiple group
comparisons. An unpaired two-tailed Student’s t-test was
used to test the percentage differences for statistical signifi-
cance. Significance was accepted at P < 0.05.
Results
Characterization of Cell Cultures
Phase microscopy of tendon cell cultures revealed a mixture of
cell types derived from tendon tissue. Morphologically,
epitendon (sheath) cells appear as large oval fibroblasts while
tenocytes are small spindle-shaped fibroblasts. Ligament and
chondrocyte cultures were homogeneous in cell type.
Upregulation of Collagen Synthesis
An inverse dose–response in uptake of tritiated proline into
collagenase-sensitive material was observed in all three
cell types exposed to varying dosages of CDS (Table 1). In
each cell type, maximum uptake into collagen occurred at
1–10 mgm l
 1, the lowest doses tested. At doses higher than
50 mgm l
 1, no effect or slight inhibition of collagen synthesis
was noted (Table 1). The sensitivity of response of each
cell type with regard to collagen synthesis was ligament cells
(þ 69%)   chondrocytes (þ 56%) > tenocytes (þ 22%).
Confirmation of CDS-induced stimulation of collagen
synthesis was observed by assessment of the specific activity
of hyp and pro. Expressed as a percentage change from control
cultures, the specific activity of hyp in ligament cells was
significantly greater than that in tenocytes or epitendon cells
(132% versus 27% and 49%) (chondrocytes not analyzed)
(Table 2).
Calculation of Collagen to NCP Ratio
In Method 2, calculation of NCP synthesis was based on the
assumption that the ratio of pro to hyp in type I collagen was
similar to that in type II collagen and is equal to 1.42. It also
assumes that the specific activity of the two imino acids is
identical since hyp derives from pro in post-translational
reactions. Hence, the synthesis of NCP was calculated as:
Labeledhyp·1:42¼labeledproincollagen
Totallabeledpro labeledproincollagen¼labeledproinNCP
Based on this information, the ratio of collagen to NCP
synthesis in the three cell types was calculated by
measurement of the amount of labeled proline in collagen
and NCP. The data presented in Table 3 indicate that
Table 1. Collagen synthesis by chondrocytes, ligament cells and tenocytes exposed to varying doses of CDS
Control IGF (50 ng ml
 1) CDS (1 mgm l
 1) CDS (10 mgm l
 1) CDS (50 mgm l
 1) CDS (100 mgm l
 1)
Chondrocytes 380 (60) 600 (96)
† 592 (112)
† 560 (60)
† 580 (112) 352 (58)
Ligament Cells 520 (32) 944 (132)
† 880 (120)
† 920 (148)
† 656 (120) 576 (56)
Tenocytes 316 (43) 460 (35)
† 385 (35)
† 419 (30)
† 364 (45) 345 (43)
Data presented as Mean (±SEM) (n ¼ 8) CPM tritiated proline uptake into collagenase-sensitive material (collagen).
†Denotes statistical significance at P < 0.05 to 0.001.
Table 2. Comparative analysis of hydroxyproline and proline-specific activity in collagen of connective tissue cells exposed to CDS and IGF-1
Assay Ligament Tendon Epitendon
Control CDS IGF Control CDS IGF Control CDS IGF
SA Hyp 68 (13) 158
† (35) 195
† (38) 250 (23) 318
† (25) 626
† (120) 378 (45) 563
† (120) 740
† (160)
SA Pro 120 (26) 196
† (25) 348
† (69) 230 (35) 326
† (45) 555
† (110) 180 (24) 167 (28) 300
† (55)
Data given as Mean (±SEM) specific activity (cpm hyp mg
 1 hyp and cpm pro mg
 1 pro) in cultures exposed to agents for 48 h.
†Indicates values statistically significant from control value at P < 0.05.
eCAM 2007;(4)2 221IGF-1 has a greater stimulatory effect on collagen
synthesis versus NCP synthesis in both chondrocytes and
tenocytes but not on ligament cells. In contrast, exposure
to CDS did not significantly alter the collagen to NCP
ratio from control values in any cell type.
Discussion
The combination of glcN and CS effectively stimulates
neosynthesis of collagen in cell cultures of ligament,
tendon and cartilage tissue. Based on the ratio 5:4:1 of the
commercial product Cosamin DS, a 10 mgm l
 1 dose exposed
cells to 5 mgm l
 1 glucosamine ( 23 mM), 4 mgm l
 1 CS
( 0.25 mM) and 1 mgm l
 1 Mn ascorbate. In comparison to in
vivo levels, CS at 0.25 mM is probably at the low range of that
obtainable with repeated dosing (26). The doses of glcN
are within the range of serum levels according to the latest
published data [23 mM versus 10–60 mM (27,28)]. The effects
noted in vitro can be attributed to glucosamine and CS
since our media contained 50 mgm l
 1 ascorbate, negating
any effect by the small amount of ascorbate present in the
formula.
We observed these results under in vitro conditions in media
containing glucose at levels existing in serum and at cell
densities known to maintain cell phenotype (29). Standard
DMEM/F-12 culture media, optimized for cell growth,
contains 17 mM of glucose. Such high levels of sugar may
be found in serum of diabetics while normal serum levels
of glucose are closer to 5 mM. Previous studies using
fibroblastic-like cells indicate that high glucose levels
(>5 mM) reduce collagen type I synthesis (30,31). In a
preliminary study using chondrocytes, we observed up to a
28% reduction in radiolabeled proline uptake into collagenase-
sensitive material at 17 mM glucose compared to 5 mM
glucose (data not presented). The addition of 1% fetal calf
serum was considered to be the minimal amount necessary for
maintenance and adherence of the cells in culture.
Epitenon cells are considered to be the collagen-producing
cells involved in healing of tendons (21), but in vivo ligaments
are considered to be functionally and metabolically the more
active tissue compared to tendons or chondrocytes (32). Our
data confirms these findings insofar as ligament cells
incorporated almost twice the radioactivity into collagenase-
sensitive material than tenocytes or chondrocytes (Table 1).
This was also seen in calculation of the specific activity of hyp
(þ132% in ligament versus þ27% in tenocytes). Interestingly,
when comparing the ratio of radiolabeled proline in collagen
versus radiolabeled proline in NCP, a 3-fold increase was seen
with IGF-1 in chondrocytes and tenocytes but not ligament
cells. Moreover, the ratio in cells exposure to CDS did not
significantly differ from controls. This suggests that the
response of chondrocytes and tenocytes to CDS may differ
mechanistically from that of IGF-1.
Few publications have been devoted to the effect of glcN or
CS on collagen synthesis. Bassleer et al. (33) found that CS
had no effect on human cartilage collagen synthesis and
Anderson et al. (34) failed to detect an effect of glucosamine
on canine chondrocyte collagen synthesis. However, the data
of Jimenez et al. (35) and O’Grady et al. (36) indicate
increased gene expression for collagen synthesis with both
agents as well as with a combination of agents. The disparity in
results may be a reflection of the doses used, the culture
system, i.e. cells clusters versus explants or may indicate that
the increase in mRNA levels is not reflected in the actual
assayable final product.
The inhibitory effect of high levels of CS on glycosami-
noglycan synthesis by chondrocytes has been observed by
others (9,37). Although our preparation consisted of a mixture
of glcN and CS, the inhibition of collagen synthesis observed
at doses higher than 50 mgm l
 1 (20 mgm l
 1 CS) suggest that
the effect is due to the CS component. An explanation for
the inverse dose–response of connective tissue cells to CS
was not investigated in this study nor has any explanation been
forthcoming by other authors (9,37). It may be a reasonable
conjecture that the response resembles a typical non-
monotonic dose–response (i.e. a non-linear curve where the
slope of the dose–response reverses sign somewhere along the
curve).
There are several complementary and alternative therapies
related to connective tissue metabolism and repair. For
example, a recent review by Ahmed et al. (38) describes the
use of botanicals in osteoarthritis. Bromelain (39) and bee
venom acupuncture (40) have also been proposed for a similar
application. The addition of glucosamine and CS to the list of
alternative therapies provides an additional tool to alternative
non-invasive treatment.
The clinical significance of these data relates to documenta-
tion that patients with meniscus and ligament injuries of the
knee have a high incidence of developing degenerative
radiological changes within a 10–20 year period (14). Since
collagen is the major component of these tissues, our
hypothesis is that upregulation of its synthesis by a combina-
tion of glcN and CS may accelerate tissue repair and diminish
the probability of OA development. However, it is too prema-
ture to extrapolate our in vitro data to in vivo circumstances
by stating that these agents accelerate ligament and tendon
healing. However, under conditions of trauma/stress where
collagen degradation is occurring the combination of glcN and
CS may circumvent and/or accelerate repair processes (Fig. 1).
It should also be noted that these results pertain to in vitro
direct effects of the agents on connective tissue cell
metabolism. Clinical efficacy in vivo relates to symptomatic
Table 3. Ratio of labeled proline in collagen to labeled proline in NCP
Chondrocytes Tenocytes Ligament cells
Control 1.09 (0.12) 0.72 (0.11) 0.90 (0.08)
CDS 0.80 (0.04) 1.06 (0.10) 0.97 (0.25)
IGF-1 3.15 (0.66)
† 2.15 (0.55)
† 0.83 (0.20)
Data expressed as ratio of CPM (±SEM) of labeled proline in collagen versus
labeled proline in NCP.
†Indicates statistically significant at P < 0.05.
222 Nutraceutical Stimulation of Collagen Synthesisrelief by virtue of their anti-inflammatory action and therefore
does not necessarily equate to the observed metabolic
responses.
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